About Enterococcus
Covers E. faecium (the strain usually intended, e.g. SF68/Cylactin, with some diarrhea RCTs) and E. faecalis. Graded low despite some trials because Enterococcus species are also opportunistic pathogens and can carry transferable antibiotic-resistance genes (notably vancomycin resistance); regulatory bodies (EFSA) apply caution. Evidence is strain-specific and safety context matters.
What Enterococcus supports
- E. faecium SF68 has some evidence for diarrhea (strain-specific)
- Safety context matters: genus includes opportunistic pathogens
How much Enterococcus to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1–10
billion_cfu
SF68 diarrhea RCTs use ~7.5 billion CFU/day; no universal dose. Presence-only in blends; nominal range.
Clinical evidence
Limited clinical evidence. Low: limited strain RCTs offset by pathogen/resistance safety concerns.
Examine.com